MAPK7 and cancer: Moreover, it has been recently reported that INY-06-061, a potent and highly selective heterobifunctional degrader of ERK5, did not induce anti-proliferative effects in multiple cancer cell lines nor suppress inflammatory responses in primary endothelial cells (ECs) [56].